Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press23810.17650/2220-3478-2018-8-1-11-18REVIEWОБЗОРЫ ЛИТЕРАТУРЫRole of antiangiogenic agents in the treatment of metastatic colorectal cancerРоль антиангиогенных препаратов в лечении больных метастатическим колоректальным ракомZabelinM. V.ЗабелинМ. В.
Russian Federation
maximzabelin@mail.ruGordeevS. S.ГордеевС. С.
Russian Federation
PetrovL. O.ПетровЛ. О.
Russian Federation
https://orcid.org/0000-0002-0792-6012KostinA. A.КостинА. А.
Russian Federation
VarlamovaS. E.ВарламоваС. Е.
Russian Federation
Federal Medical and Biological Agency of RussiaФедеральное медико-биологическое агентство РоссииN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииP.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииNational Medical Radiology Research Center, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииState Research Center – Burnasyan Federal Medical Biophysical Center, Federal Medical and Biological Agency of RussiaФГБУ «Государственный научный центр РФ – Федеральный медицинский биофизический центр им. А.И. Бурназяна» ФМБА России290520188111182905201829052018Copyright ©; 2018, ABV-pressCopyright ©; 2018, АБВ-пресс2018ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/238

This review covers the latest data on antiangiogenic agents used in patients with colorectal cancer. In this article, we describe drugs that have already been included into therapy regimens for colorectal cancer and vascular endothelial growth factor (VEGF) inhibitors that have been approved for other indications. Targeted drugs with a similar mechanism of action that are currently in clinical trials are discussed separately. VEGF-inhibitors are one of the main groups of targeted drugs for colorectal cancer with an acceptable toxicity profile, which can be used both in combination with chemotherapeutic agents and as maintenance treatment. Moreover, these drugs are not dependent on mutational status, which is a significant advantage.

В статье приводится обзор современных данных литературы о применении антиангиогенных препаратов в лечении больных колоректальным раком. Рассматриваются как препараты, уже использующиеся в схемах терапии рака толстой кишки, так и ингибиторы VEGF, зарегистрированные для других показаний. Отдельно обсуждаются таргетные препараты со схожим механизмом действия, находящиеся на стадии клинических испытаний. Ингибиторы VEGF – одна из основных групп таргетных препаратов в лечении больных колоректальным раком, с приемлемым профилем токсичности, доступная к использованию как в сочетании с химиотерапией, так и в качестве поддерживающего лечения. Одним из преимуществ их использования является отсутствие зависимости от мутационного статуса пациента.

 

colorectal cancerrectal cancertargeted therapyVEGF inhibitorsколоректальный ракрак прямой кишкитаргетная терапияингибиторы VEGF1. Федянин М., Трякин А., Тюляндин С. Таргетные препараты в терапии рака толстой кишки. Эффективная фармакотерапия 2012;(36):30–7. [Fedyanin M., Tryakin A., Tyulyandin S. Targeted drugs in the treatment of colon cancer. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2012;(36):30–7. (In Russ.)].Федянин М., Трякин А., Тюляндин С. Таргетные препараты в терапии рака толстой кишки. Эффективная фармакотерапия 2012;(36):30–7. [Fedyanin M., Tryakin A., Tyulyandin S. Targeted drugs in the treatment of colon cancer. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2012;(36):30–7. (In Russ.)].2. Кузнецова О., Хадашева З., Смирнова И. Ингибиторы фактора роста эндотелия сосудов и тирозинкиназных рецепторов как направление антиангиогенной терапии опухолей. Вестник Чеченского государственного университета 2016;(4):60–6. [Kuznetsova O., Khadasheva Z., Smirnova I. Inhibitors of vascular endothelial growth factor and tyrosine kinase receptors in antiangiogenic therapy of tumors. Vestnik Chechenskogo gosudarstvennogo universiteta = Bulletin of the Chechen State University 2016;(4):60–6. (In Russ.)].Кузнецова О., Хадашева З., Смирнова И. Ингибиторы фактора роста эндотелия сосудов и тирозинкиназных рецепторов как направление антиангиогенной терапии опухолей. Вестник Чеченского государственного университета 2016;(4):60–6. [Kuznetsova O., Khadasheva Z., Smirnova I. Inhibitors of vascular endothelial growth factor and tyrosine kinase receptors in antiangiogenic therapy of tumors. Vestnik Chechenskogo gosudarstvennogo universiteta = Bulletin of the Chechen State University 2016;(4):60–6. (In Russ.)].3. Якушева Т. А., Когония Л., Федотов А. и др. Авастин в лечении метастатического колоректального рака. Российский биотерапевтический журнал 2010;9(4):35–8. [Yakusheva T. A., Kogoniya L., Fedotov A. et al. Avastin in the treatment of metastatic colorectal cancer. Rossiyskiy bioterapevtycheskiy zhurnal = Russian biotherapeutic journal 2010;9(4):35–8. (In Russ.)].Якушева Т. А., Когония Л., Федотов А. и др. Авастин в лечении метастатического колоректального рака. Российский биотерапевтический журнал 2010;9(4):35–8. [Yakusheva T. A., Kogoniya L., Fedotov A. et al. Avastin in the treatment of metastatic colorectal cancer. Rossiyskiy bioterapevtycheskiy zhurnal = Russian biotherapeutic journal 2010;9(4):35–8. (In Russ.)].4. Трякин А. А. Таргетная терапия колоректального рака, рака желудка и поджелудочной железы. Практическая онкология 2010;11(3):143. [Tryakin A. A. Targeted therapy for colorectal cancer, gastric, and pancreatic cancer. Prakticheskaya onkologiya = Practical Oncology 2010;11(3):143. (In Russ.)].Трякин А. А. Таргетная терапия колоректального рака, рака желудка и поджелудочной железы. Практическая онкология 2010;11(3):143. [Tryakin A. A. Targeted therapy for colorectal cancer, gastric, and pancreatic cancer. Prakticheskaya onkologiya = Practical Oncology 2010;11(3):143. (In Russ.)].5. Переводчикова Н. Таргетные препараты и их место в современной терапии опухолевых заболеваний. Клиническая онкогематология. Фундаментальные исследования и клиническая практика 2009;2(4):367–73. [Perevodchikova N. Targeted drugs and their role in cancer treatment. Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Fundаmental Research and Clinical Practice 2009;2(4):367–73. (In Russ.)].Переводчикова Н. Таргетные препараты и их место в современной терапии опухолевых заболеваний. Клиническая онкогематология. Фундаментальные исследования и клиническая практика 2009;2(4):367–73. [Perevodchikova N. Targeted drugs and their role in cancer treatment. Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Fundаmental Research and Clinical Practice 2009;2(4):367–73. (In Russ.)].6. Grothey A., Hedrick E. E., Mass R. D. et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008;26(2):183–9. PMID: 18182660. DOI: 10.1200/JCO.2007.13.8099.Grothey A., Hedrick E. E., Mass R. D. et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008;26(2):183–9. PMID: 18182660. DOI: 10.1200/JCO.2007.13.8099.7. Saltz L., Clarke S., Diaz-Rubio E. et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 2007;25(18 Suppl): 4028.Saltz L., Clarke S., Diaz-Rubio E. et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 2007;25(18 Suppl): 4028.8. De Gramont A., Van Cutsem E., Schmoll H.-J. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012;13(12):1225–33. PMID: 23168362. DOI: 10.1016/S1470–2045(12)70509-0.De Gramont A., Van Cutsem E., Schmoll H.-J. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012;13(12):1225–33. PMID: 23168362. DOI: 10.1016/S1470–2045(12)70509-0.9. Allegra C. J., Yothers G., O’Connell M. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29(1):11–6. PMID: 20940184. DOI: 10.1200/JCO.2010.30.0855.Allegra C. J., Yothers G., O’Connell M. J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29(1):11–6. PMID: 20940184. DOI: 10.1200/JCO.2010.30.0855.10. Bennouna J., Sastre J., Arnold D. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29–37. PMID: 23168366. DOI: 10.1016/S1470–2045(12)70477-1.Bennouna J., Sastre J., Arnold D. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29–37. PMID: 23168366. DOI: 10.1016/S1470–2045(12)70477-1.11. Simkens L. H., van Tinteren H., May A. et al. Maintenance treatment with cape-citabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385(9980):1843–52. PMID: 25862517. DOI: 10.1016/S0140-6736(14)62004-3.Simkens L. H., van Tinteren H., May A. et al. Maintenance treatment with cape-citabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385(9980):1843–52. PMID: 25862517. DOI: 10.1016/S0140-6736(14)62004-3.12. Феоктистова П., Загинайко А., Карасева В. и др. Таргетная терапия метастатического колоректального рака. Здравоохранение Югры: опыт и инновации 2016;(спецвыпуск):76–84. [Feoktistova P., Zaginayko A., Karaseva V. et al. Targeted therapy for metastatic colorectal cancer. Zdravookhranenie Yugry: opyt i innovatsii = Health Care in Ugra: Experience and Innovation 2016;(special issue): 76–84. (In Russ.)].Феоктистова П., Загинайко А., Карасева В. и др. Таргетная терапия метастатического колоректального рака. Здравоохранение Югры: опыт и инновации 2016;(спецвыпуск):76–84. [Feoktistova P., Zaginayko A., Karaseva V. et al. Targeted therapy for metastatic colorectal cancer. Zdravookhranenie Yugry: opyt i innovatsii = Health Care in Ugra: Experience and Innovation 2016;(special issue): 76–84. (In Russ.)].13. Смагулова К. Оценка качества жизни при лечении метастатического рака толстой и прямой кишок. Успехи современной науки 2017;1(6):81–3. [Smagulova K. Assessing the quality of life during therapy for metastatic colorectal cancer. Uspekhi sovremennoy nauki = Modern Science Success 2017;1(6):81–3. (In Russ.)].Смагулова К. Оценка качества жизни при лечении метастатического рака толстой и прямой кишок. Успехи современной науки 2017;1(6):81–3. [Smagulova K. Assessing the quality of life during therapy for metastatic colorectal cancer. Uspekhi sovremennoy nauki = Modern Science Success 2017;1(6):81–3. (In Russ.)].14. Yamaguchi K., Taniguchi H., Komori A. et al. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colo-rectal cancer. BMC Cancer 2015;(15):601. DOI: 10.1186/s12885-015-1606-1.Yamaguchi K., Taniguchi H., Komori A. et al. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colo-rectal cancer. BMC Cancer 2015;(15):601. DOI: 10.1186/s12885-015-1606-1.15. Воронцова К., Черноглазова Е., Вышинская Г. Таргетные препараты во второй линии противоопухолевой терапии диссеминированного колоректального рака. Медицинский совет 2015;(8):91–2. [Vorontsova K., Chernoglazova E., Vyshinskaya G. Targeted drugs in second-line therapy for disseminated colorectal cancer. Meditsinskiy sovet = Medical Council 2015;(8):91–2. (In Russ.)].Воронцова К., Черноглазова Е., Вышинская Г. Таргетные препараты во второй линии противоопухолевой терапии диссеминированного колоректального рака. Медицинский совет 2015;(8):91–2. [Vorontsova K., Chernoglazova E., Vyshinskaya G. Targeted drugs in second-line therapy for disseminated colorectal cancer. Meditsinskiy sovet = Medical Council 2015;(8):91–2. (In Russ.)].16. Лихова Е. А., Юкальчук Д., Пономаренко Д. и др. Клинический опыт применения препарата афлиберцепт во второй линии терапии метастатического колоректального рака. Эффективная фармакотерапия 2017;(20):38–40. [Likhova E. A., Yukalchuk D., Ponomarenko D. et al. Clinical experience with aflibercept in second-line treatment of metastatic colorectal cancer. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2017;(20):38–40. (In Russ.)].Лихова Е. А., Юкальчук Д., Пономаренко Д. и др. Клинический опыт применения препарата афлиберцепт во второй линии терапии метастатического колоректального рака. Эффективная фармакотерапия 2017;(20):38–40. [Likhova E. A., Yukalchuk D., Ponomarenko D. et al. Clinical experience with aflibercept in second-line treatment of metastatic colorectal cancer. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2017;(20):38–40. (In Russ.)].17. Tang P. A., Moore M. J. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap Adv Gastroenterol 2013;6(6):459–73. DOI: 10.1177/1756283X13502637.Tang P. A., Moore M. J. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap Adv Gastroenterol 2013;6(6):459–73. DOI: 10.1177/1756283X13502637.18. Tabernero J., Van Cutsem E., Lakomý R. et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014;50(2):320–31. DOI: 10.1016/ j.ejca.2013.09.013.Tabernero J., Van Cutsem E., Lakomý R. et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014;50(2):320–31. DOI: 10.1016/ j.ejca.2013.09.013.19. Bordonaro R., Frassineti G. L., Ciuffreda L. et al. Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients age 65 or older. J Clin Oncol 2015;32(suppl): 545. DOI: 10.1200/jco. 2014.32.3_suppl. 545.Bordonaro R., Frassineti G. L., Ciuffreda L. et al. Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients age 65 or older. J Clin Oncol 2015;32(suppl): 545. DOI: 10.1200/jco. 2014.32.3_suppl. 545.20. Секачева М. И. Регорафениб: новый препарат для лечения метастатического колоректального рака. Злокачественные опухоли 2016;2(18):72–80. [Sekacheva M. I. Regorafenib: a new drug for treatment of metastatic colorectal cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;2(18):72–80. (In Russ.)].Секачева М. И. Регорафениб: новый препарат для лечения метастатического колоректального рака. Злокачественные опухоли 2016;2(18):72–80. [Sekacheva M. I. Regorafenib: a new drug for treatment of metastatic colorectal cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;2(18):72–80. (In Russ.)].21. Grothey A., Van Cutsem E., Sobrero A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-control led, phase 3 trial. Lancet 2013;381(9863): 303–12. DOI: 10.1016/S0140-6736(12) 61900-X.Grothey A., Van Cutsem E., Sobrero A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-control led, phase 3 trial. Lancet 2013;381(9863): 303–12. DOI: 10.1016/S0140-6736(12) 61900-X.22. Li J., Qin S., Xu R. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015;16(6):619–29. DOI: 10.1016/S1470-2045(15)70156-7.Li J., Qin S., Xu R. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015;16(6):619–29. DOI: 10.1016/S1470-2045(15)70156-7.23. Chow L. Q., Eckhardt S. G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884–96. PMID: 17327610. DOI: 10.1200/JCO.2006.06.3602.Chow L. Q., Eckhardt S. G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884–96. PMID: 17327610. DOI: 10.1200/JCO.2006.06.3602.24. Saltz L. B., Rosen L. S., Marshall J. L. et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007;25(30):4793–9. PMID: 17947727. DOI: 10.1200/JCO.2007.12.8637.Saltz L. B., Rosen L. S., Marshall J. L. et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007;25(30):4793–9. PMID: 17947727. DOI: 10.1200/JCO.2007.12.8637.25. Carrato A., Swieboda-Sadlej A., Staszewska-Skurczynska M. et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 2013;31(10):1341–7. PMID: 23358972. DOI: 10.1200/JCO.2012.45.1930.Carrato A., Swieboda-Sadlej A., Staszewska-Skurczynska M. et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 2013;31(10):1341–7. PMID: 23358972. DOI: 10.1200/JCO.2012.45.1930.26. George S., Blay J., Casali P. et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45(11):1959–68. PMID: 19282169. DOI: 10.1016/j.ejca.2009.02.011.George S., Blay J., Casali P. et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45(11):1959–68. PMID: 19282169. DOI: 10.1016/j.ejca.2009.02.011.27. Wilhelm S., Carter C., Lynch M. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5(10):835–44. PMID: 17016424. DOI: 10.1038/nrd2130.Wilhelm S., Carter C., Lynch M. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5(10):835–44. PMID: 17016424. DOI: 10.1038/nrd2130.28. Tabernero J., Garcia-Carbonero R., Cassidy J. et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res 2013;19(9):2541–50. PMID: 23532888. DOI: 10.1158/1078-0432. CCR-13–0107.Tabernero J., Garcia-Carbonero R., Cassidy J. et al. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. Clin Cancer Res 2013;19(9):2541–50. PMID: 23532888. DOI: 10.1158/1078-0432. CCR-13–0107.29. Krupitskaya Y., Wakelee H. A. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009;10(6):597–605. PMID: 19513949.Krupitskaya Y., Wakelee H. A. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009;10(6):597–605. PMID: 19513949.30. Tabernero J., Yoshino T., Cohn A. L. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16(5):499–508. PMID: 25877855. DOI: 10.1016/S1470-2045(15)70127-0.Tabernero J., Yoshino T., Cohn A. L. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16(5):499–508. PMID: 25877855. DOI: 10.1016/S1470-2045(15)70127-0.31. Lin E. H., Lenz H. J., Saleh M. N. et al. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1(IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Med 2014;3(4):988–97. PMID: 24905030. DOI: 10.1002/cam4.263.Lin E. H., Lenz H. J., Saleh M. N. et al. A randomized, phase II study of the anti-insulin-like growth factor receptor type 1(IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer. Cancer Med 2014;3(4):988–97. PMID: 24905030. DOI: 10.1002/cam4.263.32. Weekes C. D., Beeram M., Tolcher A. W. et al. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs 2014;32(4):653–60. PMID: 24604265. DOI: 10.1007/s10637-014-0071-z.Weekes C. D., Beeram M., Tolcher A. W. et al. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs 2014;32(4):653–60. PMID: 24604265. DOI: 10.1007/s10637-014-0071-z.33. Patnaik A., LoRusso P. M., Messersmith W. A. et al. A phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73(5):951–60. PMID: 24633809. DOI: 10.1007/s00280-014-2426-8.Patnaik A., LoRusso P. M., Messersmith W. A. et al. A phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73(5):951–60. PMID: 24633809. DOI: 10.1007/s00280-014-2426-8.34. LoRusso P. M., Krishnamurthi S., Youssoufian H. et al. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs 2014;32(2):303–11. PMID: 23903897. DOI: 10.1007/s10637-013-9998-8.LoRusso P. M., Krishnamurthi S., Youssoufian H. et al. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs 2014;32(2):303–11. PMID: 23903897. DOI: 10.1007/s10637-013-9998-8.35. Moore M., Gill S., Asmis T. et al. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Ann Oncol 2016;27(12):2216–24. PMID: 27733377. DOI: 10.1093/annonc/mdw412.Moore M., Gill S., Asmis T. et al. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Ann Oncol 2016;27(12):2216–24. PMID: 27733377. DOI: 10.1093/annonc/mdw412.36. Peeters M., Strickland A., Lichinitser M. et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013;108(3):503–11. PMID: 23361051. DOI: 10.1038/bjc.2012.594.Peeters M., Strickland A., Lichinitser M. et al. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013;108(3):503–11. PMID: 23361051. DOI: 10.1038/bjc.2012.594.